The bipartisan support for the Pharmacy and Medically Underserved Areas Enhancement Act demonstrates that legislators and policymakers recognize the value pharmacists bring to patients and the U.S. healthcare system. USP applauds this step and supports swift passage of this important legislation.
Legislation being considered by Congress will remove the requirement that all biologic medicines – drugs such as insulin, vaccines, cancer treatments and other therapies made using living matter – comply with public quality standards of the U.S. Pharmacopeia (USP). This same legislation would also apply to biosimilars. As a result, public confidence in biologics and biosimilars as well as patient safety would be at risk. Learn more.
For a hundred years, federal law has required that all drugs adhere to public quality standards—part of ensuring safety and protecting the public’s health. Language that would exempt biologics, including biosimilars, from adhering to the same public quality standards as other prescription medicines was recently added to the FDA and NIH Workforce Authorities Modernization Act. Learn about the potential impact this biologics quality exemption may have on competition, product development, and the public's confidence in biologics and biosimilars.
India is a prominent player in today’s global pharmaceutical arena and a major contributor to the world’s supply of medicines. A large number of generics and OTC medicines in the U.S. are imported from India, which makes USP's collaborations with Indian pharma critical.
USP's CEO Dr. Ron Piervincenzi relays his experiences and lessons learned from the 68th World Health Assembly held in Geneva, Switzerland, which he recently attended as a private advisor to the U.S. delegation led by Secretary of Health and Human Services, Sylvia Burwell.